Too Much of a Good Thing? Chronic IFN Fuels Resistance to Cancer Immunotherapy

Publication date: 20 December 2016
Source:Immunity, Volume 45, Issue 6
Author(s): James L. Reading, Sergio A. Quezada
Immune checkpoint blockade (ICB) is revolutionizing cancer medicine, yet the molecular basis of resistance remains unclear. In a recent issue of Cell, Benci et al. (2016) demonstrate that sustained interferon signaling is central to the development of PD-L1-dependent and -independent resistance to ICB.

Teaser

Immune checkpoint blockade (ICB) is revolutionizing cancer medicine, yet the molecular basis of resistance remains unclear. In a recent issue of Cell, Benci et al. (2016) demonstrate that sustained interferon signaling is central to the development of PD-L1-dependent and -independent resistance to ICB.


http://ift.tt/2hFKUQE